ASAM Pocket Guidelines and Patient Guide

Stimulant Use Disorder

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1519511

Contents of this Issue

Navigation

Page 29 of 29

Abbreviations A-CRA, adolescent community reinforcement approach; ACS, acute coronary syndrome; ADHD, attention-deficit/hyperactivity disorder; ATS, amphetamine-type stimulant; AUD, alcohol use disorder; BID, two times per day; BZD, benzodiazepine; CBC, complete blood count; CBT, cognitive behavioral therapy; CK, creatine kinase; CM, contingency management; CMP, comprehensive metabolic panel; CRA, community reinforcement approach; d-AMP, dextroamphetamine; d-AMP-SR, sustained-release dextroamphetamine; DSM, Diagnostic and Statistical Manual of Mental Disorders; ECG, electrocardiogram; ED, emergency department; ER, extended release; FDA, United States Food and Drug Administration; GABA, gamma-aminobutyric acid; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICU, intensive care unit; IM, intramuscular; IPV, intimate partner violence; IV, intravenous; LDX, lisdexamfetamine; LFT, liver function test; MAS-ER, extended-release mixed amphetamine salts; MET, motivational enhancement therapy; MI, motivational interviewing ; MPH, methylphenidate; MSK, musculoskeletal; NMDA, N-methyl-D- aspartate; PBO, phenobarbital; PDMP, prescription drug monitoring program; PEP, postexposure prophylaxis; PO, per os (by mouth/oral); PrEP, preexposure prophylaxis; RSS, recovery support services; SCS, supervised consumption sites; SGM, sexual and gender minoritized; STI, sexually transmitted infection; StUD, stimulant use disorder; SUDs, substance use disorders; TID, three times per day; TUD, tobacco use disorder; USPSTF, United States Preventive Services Task Force; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children Source e ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder. Available at: https://www.asam.org/quality-care/clinical-guidelines/stimulant- use-disorders. Guideline Committee Members Steven Batki, MD; Daniel Ciccarone, MD, MPH; Scott E. Hadland, MD, MPH; Brian Hurley, MD (Co-Chair); Kimberly Kabernagel, DO; Frances Levin, MD; James McKay, PhD; Larissa Mooney, MD (Co-Chair); Siddarth Puri, MD; Richard Rawson, PhD; Andrew Saxon, MD; Kevin Sevarino, MD, PhD; Kevin Simon, MD; Timothy Wiegand, MD Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. 1258 Upsala Rd Sanford, FL 32771 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2024 All rights reserved ASAMSUD04243a

Articles in this issue

Links on this page

view archives of ASAM Pocket Guidelines and Patient Guide - Stimulant Use Disorder